Lakewood-Amedex Biotherapeutics holds annual shareholder meeting

• Lakewood-Amedex Biotherapeutics held its annual shareholder meeting on Sept. 22, 2026.
• Shareholders backed an articles amendment raising authorized common shares to 100,000,000 from 12,500,000.
• Investors also authorized the board to execute one or more reverse stock splits, up to a cumulative 1-for-20 ratio.
• An amendment to the 2020 equity incentive plan was adopted, lifting the share pool to 400,000.
• CBIZ CPAs was ratified as independent registered public accounting firm.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-104177), on September 29, 2026, and is solely responsible for the information contained therein.